![[logo] US EPA](https://webarchive.library.unt.edu/eot2008/20090507224044im_/http://www.epa.gov/epafiles/images/logo_epaseal.gif){kind=logo}
Nanotechnology: Characterization of Nanoparticles Intended for Cancer Therapeutics and Diagnostics
Highlights
February 12, 2008 - Read the Federal Register notice about EPA's Nanotechnology Research Strategy and meeting to review public comment:
- FR Notice Requesting Public comment on EPA's Nanotechnology Research Strategy and comment review meeting (PDF) (3 pp, 53 K)
- EPA's draft Nanotechnology Research Strategy (PDF) (76 pp, 1.10 MB)
 |
Nanotechnology Search
The Nanotechnology Characterization Laboratory (NCL) conducts preclinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics and diagnostics. The NCL is a collaborating partnership between NCI, the U.S. Food and Drug Administration and the National Institute of Standards and Technology. As part of its assay cascade, NCL characterizes nanoparticles' physical attributes, their in vitro biological properties, and their in vivo compatibility using animal models. The Laboratory facilitates the rapid transition of basic nanoscale particles and devices into clinical applications by providing the critical infrastructure and characterization services to nanomaterial providers. It is a national resource available to investigators from academia, industry and government. The presentation will provide an overview of the NCL; discuss parameters that are critical to biocompatibility, and present assays used for preclinical characterization of nanoparticles.